$VKTX

Revolution Medicines' pancreatic cancer drug approval validated its technology and supported its $40B+ valuation. Summit Therapeutics, Abivax, and Viking Therapeutics, each with multibillion-dollar valuations, face key tests for their experimental drugs. Summit awaits FDA decision on ivonescimab for lung cancer; Abivax eyes 2026 FDA filing for obefazimod in ulcerative colitis; Viking develops obesity treatments to compete with market leaders.

Viking Therapeutics (VKTX) reports Q3 2026 results on Oct 28. Shares fell 41.42% in the past month. The company lost $1.10 per share in Q2, beating estimates. It raised $500M and launched a Phase 3 oral obesity drug trial. Analysts expect a wider loss. Management will discuss the oral program and maintenance data.

Viking Therapeutics (VKTX) fell 2.35% to $25.76, underperforming broader markets. The stock has dropped 36.66% over the past month. The company is expected to report earnings on October 28, 2026, with an estimated EPS of -$1, reflecting a 23.46% decline year-over-year. Full-year estimates project an EPS of -$4.46 and $0 revenue, changes of -39.81% and 0%, respectively. The stock has a Zacks Rank of #2 (Buy).

Viking Therapeutics (VKTX) will release Q3 2026 financial results on October 28, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss results and corporate updates. The company is a clinical-stage biopharmaceutical firm focused on metabolic and endocrine disorders, with several programs in development, including VK2735 for obesity in Phase 3 trials.

Viking Therapeutics (VKTX) has initiated two Phase 3 trials for its oral weight loss drug, VK2735, targeting obesity and type 2 diabetes. The move follows mixed Phase 2 results, with concerns about tolerability. The company aims to improve outcomes with a longer trial duration, reduced tablet size, and lower dosing. Phase 1 data showed good tolerability, but Phase 2 had a 20% discontinuation rate due to adverse events.

Canaccord reduced its price target for Viking Therapeutics (VKTX) to $106 from $114, citing pricing changes in the obesity treatment market. The stock trades near its 52-week low at $25.05. Analysts' price targets range from $38 to $125. Viking plans a $400M public offering. Other analysts maintained or adjusted their ratings and targets based on recent study data.

Viking Therapeutics (VKTX) raised $575M via stock offering and convertible notes. Funds will support phase 3 trials for obesity and diabetes drug VK2735, with results expected in 2027-2028. The company aims to extend cash runway beyond 2028, focusing on pipeline development.

Viking Therapeutics (VKTX) shares fell 7.4% due to financing overhang from recent stock and convertible note offerings, raising dilution concerns. Investors also show caution amid competition in the obesity-drug market, despite the company advancing its VK2735 program into Phase 3. Insider sales and mixed hedge fund activity were noted.

UBS initiated coverage on Viking Therapeutics (VKTX) with a Buy rating and a $94.00 price target. The company has a $3.48B market cap, a GF Score of 34/100, and recent insider selling of $6.27M. VKTX is a clinical-stage biopharmaceutical firm focused on metabolic and endocrine disorders, with no current product revenue.

Viking Therapeutics (VKTX) has started Phase 3 trials for its oral obesity drug, VK2735. The SUNRISE program includes two studies: one for obese adults without diabetes and another for those with type 2 diabetes. Each trial will enroll 560 adults, testing four dose levels. The primary goal is to measure weight change after 68 weeks. Viking aims to expand treatment options for obesity with this once-daily oral therapy.